Gilger B C, Malok E, Stewart T, Horohov D, Ashton P, Smith T, Jaffe G J, Allen J B
Comparative Ophthalmology Research Laboratories, College of Veterinary Medicine, North Carolina State University, 27606, Raleigh, NC, USA
Vet Immunol Immunopathol. 2000 Oct 31;76(3-4):239-55. doi: 10.1016/s0165-2427(00)00219-1.
The purpose of this study was to determine the effects of an intravitreal device releasing cyclosporine A (CsA) on recurrent inflammatory episodes in experimental uveitis. Nine normal horses were immunized peripherally with H37RA-mTB antigen twice, and then received 25 microg of H37RA-mTB antigen intravitreally in the right eye and an equal volume of balanced salt solution intravitreally in the left eye. Two weeks later, the animals randomly received either a CsA or a polymer implant (without CsA) in both eyes 1 week following implantation of the devices, 25 microg of H37RA-mTB antigen was reinjected into the right eye of each animal. Clinical signs of ophthalmic inflammation were graded following injections and implantation. The animals from each group were euthanized at 3, 14, and 28 days following the second injection. Aqueous and vitreous humor protein concentrations were measured. The presence, number, and type (CD4, 5 and 8) of infiltrating inflammatory cells and amount of tissue destruction were determined. Total RNA was isolated and quantitative reverse transcriptase-polymerase chain reaction was performed for equine specific interleukin (IL) 2 and 4, interferon-gamma (IFN gamma) and beta-actin. In addition, aqueous and vitreous humor and peripheral blood were collected at the termination of the experiments and analyzed for CsA concentration by HPLC. Within 4h of the first intravitreal H37RA-mTB antigen injection, each animal developed epiphora, blepharospasm, mild corneal edema, aqueous flare, myosis, and vitreous opacity. The severity of signs peaked 48 to 72 h after injection and subsequently decreased back to normal within 14 days. Following the second injection, clinical signs in the eyes with the CsA device were less severe and significantly shorter in duration than signs with the polymer only implant eyes. Aqueous and vitreous humor protein levels, infiltrating cell numbers, total number of T-lymphocytes, and levels of IL-2 and IFN gamma-mRNA were significantly less in eyes with the CsA implant compared to eyes with the polymer only. CsA implants did not completely eliminate the development of a second ('recurrent') experimental inflammatory episode in these horses. However, the duration and severity of inflammation, cellular infiltration, tissue destruction, and pro-inflammatory cytokines RNA transcript levels were significantly less in those eyes implanted with the CsA device.
本研究的目的是确定一种释放环孢素A(CsA)的玻璃体内装置对实验性葡萄膜炎复发性炎症发作的影响。9匹正常马用H37RA - 结核分枝杆菌抗原进行两次外周免疫,然后右眼玻璃体内注射25微克H37RA - 结核分枝杆菌抗原,左眼玻璃体内注射等量的平衡盐溶液。两周后,在植入装置1周后,动物随机双眼接受CsA或聚合物植入物(不含CsA),每只动物右眼再次注射25微克H37RA - 结核分枝杆菌抗原。注射和植入后对眼部炎症的临床体征进行分级。每组动物在第二次注射后3天、14天和28天实施安乐死。测量房水和玻璃体液中的蛋白质浓度。确定浸润性炎症细胞的存在、数量和类型(CD4、5和8)以及组织破坏程度。分离总RNA,并对马特异性白细胞介素(IL)2和4、干扰素 - γ(IFNγ)和β - 肌动蛋白进行定量逆转录 - 聚合酶链反应。此外,在实验结束时收集房水、玻璃体液和外周血,并通过高效液相色谱法分析CsA浓度。在首次玻璃体内注射H37RA - 结核分枝杆菌抗原后4小时内,每只动物出现流泪、眼睑痉挛、轻度角膜水肿、房水闪光、瞳孔缩小和玻璃体混浊。体征的严重程度在注射后48至72小时达到峰值,随后在14天内恢复正常。第二次注射后,使用CsA装置的眼睛的临床体征比仅使用聚合物植入物的眼睛的体征严重程度更低,持续时间显著更短。与仅使用聚合物植入物的眼睛相比,使用CsA植入物的眼睛的房水和玻璃体液蛋白质水平、浸润细胞数量、T淋巴细胞总数以及IL - 2和IFNγ - mRNA水平显著更低。CsA植入物并未完全消除这些马中第二次(“复发”)实验性炎症发作的发生。然而,在植入CsA装置的眼睛中,炎症的持续时间和严重程度、细胞浸润、组织破坏以及促炎细胞因子RNA转录水平显著更低。